clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Empyema, Tuberculous D004654 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Serositis D012700 1 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Parotid Diseases D010305 1 associated lipids
Sacroiliitis D058566 1 associated lipids
Achlorhydria D000126 1 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Eye Infections D015817 1 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Hypoproteinemia D007019 1 associated lipids
Myxoma D009232 1 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Mastoiditis D008417 2 associated lipids
Periodontal Abscess D010508 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Iritis D007500 2 associated lipids
Parotid Neoplasms D010307 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Discitis D015299 2 associated lipids
Iris Diseases D007499 2 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Diphtheria D004165 2 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Empyema D004653 3 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Tenosynovitis D013717 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Ureteral Diseases D014515 3 associated lipids
Sporotrichosis D013174 3 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Ecchymosis D004438 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Paronychia D010304 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Fractures, Open D005597 3 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Scrub Typhus D012612 3 associated lipids
Barrett Esophagus D001471 3 associated lipids
Giardiasis D005873 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Cysts D003560 4 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Foot Diseases D005534 4 associated lipids
Ergotism D004881 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Pleural Diseases D010995 4 associated lipids
Parotitis D010309 4 associated lipids
Psittacosis D009956 4 associated lipids
Prurigo D011536 4 associated lipids
Rodent Diseases D012376 4 associated lipids
Confusion D003221 4 associated lipids
Lymphangitis D008205 4 associated lipids
Mycetoma D008271 4 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Duodenitis D004382 4 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Rickettsia Infections D012282 5 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Matta AJ et al. Punctual mutations in gene of clarithromycin-resistant in Colombian populations. 2018 World J. Gastroenterol. pmid:29662291
Zhang SH et al. The effect of virulence genotypes of on eradication therapy in children. Saudi J Gastroenterol pmid:29652033
Rodríguez-Sevilla G et al. Influence of three-dimensional lung epithelial cells and interspecies interactions on antibiotic efficacy against Mycobacterium abscessus and Pseudomonas aeruginosa. 2018 Pathog Dis pmid:29648588
Namkoong H et al. Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia. 2018 PLoS Pathog. pmid:29621339
Berende A et al. Cost-effectiveness of longer-term versus shorter-term provision of antibiotics in patients with persistent symptoms attributed to Lyme disease. 2018 PLoS ONE pmid:29608590
Mabe K et al. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan. 2018 J. Infect. Chemother. pmid:29605555
Fernandes PB et al. Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. 1987 Antimicrob. Agents Chemother. pmid:2957954
Chen SA et al. HLA-A*02:07 Allele Associates with Clarithromycin-Induced Cutaneous Adverse Drug Reactions in Chinese Patients. 2018 Basic Clin. Pharmacol. Toxicol. pmid:29575644
van Dyk M et al. Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries. 2018 Eur. J. Clin. Pharmacol. pmid:29572563
Chen J et al. Application of next-generation sequencing to characterize novel mutations in clarithromycin-susceptible Helicobacter pylori strains with A2143G of 23S rRNA gene. 2018 Ann. Clin. Microbiol. Antimicrob. pmid:29562911
Choi IJ et al. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. 2018 N. Engl. J. Med. pmid:29562147
Floyd-Reising S et al. In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. 1987 Antimicrob. Agents Chemother. pmid:2955742
Rodríguez-Sevilla G et al. Non-Tuberculous Mycobacteria multispecies biofilms in cystic fibrosis: development of an in vitro Mycobacterium abscessus and Pseudomonas aeruginosa dual species biofilm model. 2018 Int. J. Med. Microbiol. pmid:29555180
Leung WK et al. Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. 2018 Gastroenterology pmid:29550592
Kusuki M et al. Determination of the antimicrobial susceptibility and molecular profile of clarithromycin resistance in the Mycobacterium abscessus complex in Japan by variable number tandem repeat analysis. 2018 Diagn. Microbiol. Infect. Dis. pmid:29550059
Hanson CW et al. Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031). 1987 J. Clin. Microbiol. pmid:2954995
Kelly C et al. Macrolide antibiotics for bronchiectasis. 2018 Cochrane Database Syst Rev pmid:29543980
Bowie WR et al. In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. 1987 Antimicrob. Agents Chemother. pmid:2953304
Chin NX et al. Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. 1987 Antimicrob. Agents Chemother. pmid:2953303
Brennan DE et al. Can bacterial virulence factors predict antibiotic resistant infection? 2018 World J. Gastroenterol. pmid:29531461
Barry AL et al. In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. 1987 Antimicrob. Agents Chemother. pmid:2952064
Benson CA et al. In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. 1987 Antimicrob. Agents Chemother. pmid:2952063
Segreti J et al. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. 1987 Antimicrob. Agents Chemother. pmid:2952061
Reisfeld L et al. Cutaneous mycobacteriosis in a captive Amazonian manatee Trichechus inunguis. 2018 Dis. Aquat. Org. pmid:29516862
Fernandes PB et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. 1986 Antimicrob. Agents Chemother. pmid:2949695
Fiorini G et al. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice. 2018 Eur J Gastroenterol Hepatol pmid:29481383
Talarico S et al. High prevalence of Helicobacter pylori clarithromycin resistance mutations among Seattle patients measured by droplet digital PCR. 2018 Helicobacter pmid:29480566
Torpiano P and Pace D Clinically-diagnosed Mediterranean Spotted Fever in Malta. Travel Med Infect Dis pmid:29462726
Takemori N et al. A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report. 2018 J Med Case Rep pmid:29454372
Xu R et al. Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. 2018 Eur. J. Clin. Pharmacol. pmid:29453492
Bachir M et al. Primary antibiotic resistance and its relationship with cagA and vacA genes in Helicobacter pylori isolates from Algerian patients. Braz. J. Microbiol. pmid:29452847
Tsutsui A et al. Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. 2018 J. Infect. Chemother. pmid:29428566
Tarhini M et al. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy. 2018 Microb. Pathog. pmid:29428426
Kobayashi T et al. The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma. 2018 Ann. Hematol. pmid:29427183
Wang S et al. Enhanced adsorption of ionizable antibiotics on activated carbon fiber under electrochemical assistance in continuous-flow modes. 2018 Water Res. pmid:29426033
Yagbasan A et al. A Prospective, randomized study comparing 7-day and 14-day quadruple therapies as first-line treatments for helicobacter pylori infection in patients with functional dyspepsia. 2018 Niger J Clin Pract pmid:29411724
Maiolino G et al. Macrolides for KCNJ5-mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism. 2018 Blood Press. pmid:29409357
Takahashi E et al. Clarithromycin suppresses induction of monocyte chemoattractant protein-1 and matrix metalloproteinase-9 and improves pathological changes in the lungs and heart of mice infected with influenza A virus. 2018 Comp. Immunol. Microbiol. Infect. Dis. pmid:29406285
Wang YH et al. A systematic review and meta-analysis of genotypic methods for detecting antibiotic resistance in Helicobacter pylori. 2018 Helicobacter pmid:29405526
Abu-Khalaf N et al. The Taste of Commercially Available Clarithromycin Oral Pharmaceutical Suspensions in the Palestinian Market: Electronic Tongue and In Vivo Evaluation. 2018 Sensors (Basel) pmid:29401675
Ko J et al. Delayed onset Mycobacterium intracellulare keratitis after laser in situ keratomileusis: A case report and literature review. 2017 Medicine (Baltimore) pmid:29390522
Ribaldone DG et al. Helicobacter pylori eradication: poor medical compliance from East to West of the world. 2018 Scand. J. Gastroenterol. pmid:29383955
Tso S et al. Clarithromycin as a steroid sparing agent for the management of infantile bullous pemphigoid. 2018 BMJ Case Rep pmid:29374651
Hosono Y et al. The association between erythromycin monotherapy for Mycobacterium avium complex lung disease and cross-resistance to clarithromycin: A retrospective case-series study. 2018 J. Infect. Chemother. pmid:29361415
Jakubů V et al. Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015. 2017 Cent. Eur. J. Public Health pmid:29346850
Suzuki K et al. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare lung disease from post-marketing surveillance. 2018 Respir Investig pmid:29325687
Sahara S et al. Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. 2018 Digestion pmid:29310119
Mosdósi B et al. Severe acrocyanosis precipitated by cold agglutinin secondary to infection with Mycoplasma pneumoniae in a pediatric patient. 2017 Croat. Med. J. pmid:29308834
Laidler N Cutaneous infection with paucibacillary treated successfully with a modified antituberculous drug regimen. 2017 BMJ Case Rep pmid:29275384
Sue S et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. 2018 Helicobacter pmid:29271026
Lee JS et al. Implication of species change of Nontuberculous Mycobacteria during or after treatment. 2017 BMC Pulm Med pmid:29262802
Adachi T et al. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori. 2017 Oncology pmid:29258111
Nakase K et al. Long-term administration of oral macrolides for acne treatment increases macrolide-resistant Propionibacterium acnes. 2018 J. Dermatol. pmid:29235673
Yoshida S et al. Association between sequevar and antibiotic treatment outcome in patients with Mycobacterium abscessus complex infections in Japan. 2018 J. Med. Microbiol. pmid:29227218
Cho EH et al. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens. 2018 J. Infect. Chemother. pmid:29223615
Ruiter R et al. Helicobacter pylori resistance in the Netherlands: a growing problem? 2017 Neth J Med pmid:29219812
Compain F et al. In vitro activity of tedizolid against the Mycobacterium abscessus complex. 2018 Diagn. Microbiol. Infect. Dis. pmid:29217419
Li H et al. Inappropriate treatment in Helicobacter pylori eradication failure: a retrospective study. 2018 Scand. J. Gastroenterol. pmid:29214879
Jung JH et al. Clinical Outcomes of Standard Triple Therapy Plus Probiotics or Concomitant Therapy for Infection. 2018 Gut Liver pmid:29212313
Addo KK et al. Genotyping and drug susceptibility testing of mycobacterial isolates from population-based tuberculosis prevalence survey in Ghana. 2017 BMC Infect. Dis. pmid:29197331
Deng J et al. Lack of additional effects of long-term, low-dose clarithromycin combined treatment compared with topical steroids alone for chronic rhinosinusitis in China: a randomized, controlled trial. 2018 Int Forum Allergy Rhinol pmid:29195025
Beer-Davidson G et al. Detection of Helicobacter pylori in stool samples of young children using real-time polymerase chain reaction. 2018 Helicobacter pmid:29181860
Muñoz-Gómez P et al. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. 2018 Helicobacter pmid:29178562
Vaz AM et al. Capsule endoscopy in the diagnosis of disseminated complex infection. 2017 BMJ Case Rep pmid:29167222
Yatera K et al. The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases. 2017 Respir Investig pmid:29153420
Lee H et al. Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial. 2017 Trials pmid:29149904
Zagari RM et al. Treatment of Helicobacter pylori infection: A clinical practice update. 2018 Eur. J. Clin. Invest. pmid:29144559
Liu DS et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. 2018 Clin. Microbiol. Infect. pmid:29138101
Moon SH et al. Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin. 2017 J. Med. Chem. pmid:29136469
Ye JF et al. Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication. 2017 J Dig Dis pmid:29119724
Redondo JJ et al. A novel RT-PCR for the detection of Helicobacter pylori and identification of clarithromycin resistance mediated by mutations in the 23S rRNA gene. 2018 Diagn. Microbiol. Infect. Dis. pmid:29111147
Emmanuel R et al. Antimicrobial efficacy of drug blended biosynthesized colloidal gold nanoparticles from Justicia glauca against oral pathogens: A nanoantibiotic approach. 2017 Microb. Pathog. pmid:29101061
Iwamoto J et al. Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNFα Antibody in a Patient with Intestinal Behçet Disease. 2018 Intern. Med. pmid:29093413
Inagaki Y et al. Disseminated Cutaneous Infection of Mycobacterium colombiense in a Patient with Myelodysplastic Syndrome. 2018 Intern. Med. pmid:29093379
Lee MC et al. Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan. 2017 J. Antimicrob. Chemother. pmid:29091186
Carneiro MDS et al. Lack of association between rrl and erm(41) mutations and clarithromycin resistance in Mycobacterium abscessus complex. 2017 Mem. Inst. Oswaldo Cruz pmid:29091138
Cheung KS et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for : a population-based study. 2018 Gut pmid:29089382
De Francesco V et al. Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study. 2018 Dig Liver Dis pmid:29089267
Abadi ATB Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. 2017 World J. Gastroenterol. pmid:29085187
Liu W et al. Rapid detection of mutations in erm(41) and rrl associated with clarithromycin resistance in Mycobacterium abscessus complex by denaturing gradient gel electrophoresis. 2017 J. Microbiol. Methods pmid:29079298
Cerqueira RM et al. Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery. 2018 Obes Surg pmid:29076008
Jeon JS et al. Detection of clarithromycin-resistant by polymerase chain reaction using residual samples from rapid urease test. Indian J Med Microbiol pmid:29063887
Pastukh N et al. GenoType® HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. 2017 Helicobacter pmid:29058343
Giguère S et al. Antimicrobial Resistance in . 2017 Microbiol Spectr pmid:29052538
Tognetti L et al. Bullous impetigo during interstitial pneumonitis. 2017 G Ital Dermatol Venereol pmid:29050448
Chang CH et al. Non-Tuberculous Mycobacteria Infection Following Autologous Fat Grafting on the Face. 2017 Aesthet Surg J pmid:29045552
Oikawa R et al. Enrichment of Helicobacter pylori mutant strains after eradication therapy analyzed by gastric wash-based quantitative pyrosequencing. 2017 Tumour Biol. pmid:28990461
Haj Yahia S et al. Colchicine intoxication in familial Mediterranean fever patients using clarithromycin for the treatment of Helicobacter pylori: a series of six patients. 2018 Rheumatol. Int. pmid:28975396
Shaharir SS et al. Non-tuberculous mycobacterium bacteraemia in a pregnant systemic lupus erythematosus (SLE) patient: a case review and pooled case analysis. 2018 Clin. Rheumatol. pmid:28971307
Chen MJ et al. Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. 2017 J. Antimicrob. Chemother. pmid:28961996
Marsousi N et al. Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software. 2018 Biopharm Drug Dispos pmid:28960401
Moreira C et al. Symmetrical drug-related intertriginous and flexural exanthema induced by clarithromycin. An Bras Dermatol pmid:28954125
Radzikowska E et al. Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study. 2017 PLoS ONE pmid:28945804
Kim SY et al. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. 2017 Helicobacter pmid:28940815
Hu JL et al. Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China. Saudi J Gastroenterol pmid:28937021
Ikeue T et al. Pleuritis Caused by Mycobacterium kyorinense without Pulmonary Involvement. 2017 Intern. Med. pmid:28924121
Mukherjee D et al. Vancomycin and Clarithromycin Show Synergy against . 2017 Antimicrob. Agents Chemother. pmid:28923867
Popovic V et al. Mycobacterium shimoidei-cavitary pulmonary disease with favorable outcome. 2018 Folia Microbiol. (Praha) pmid:28913757
Panozzo C et al. Chemicals or mutations that target mitochondrial translation can rescue the respiratory deficiency of yeast bcs1 mutants. 2017 Biochim. Biophys. Acta pmid:28888990
Costa S et al. Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. 2017 Eur J Gastroenterol Hepatol pmid:28877088